Drug Information

Drug General Information
Drug ID
D0W9QI
Former ID
DIB002993
Drug Name
LErafAON
Synonyms
RafAON; Antisense raf oligonucleotide, NeoPharm; LErafAON, Insys; LErafAON-ETU; Liposomal antisense therapy, NeoPharm; Cancer therapeutic (antisense), NeoPharm; Liposome encapsulated c-raf antisense oligodeoxynucleotide, NeoPharm; Antisense oligonucleotides (liposome-encapsulated), NeoPharm
Drug Type
Antisense drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [521624], [527280]
Company
NeoPharm
Target and Pathway
Target(s) mRNA of RAF proto-oncogene serine/threonine-protein kinase Target Info [526998]
BioCyc Pathway MAP kinase cascade
KEGG Pathway MAPK signaling pathway
ErbB signaling pathway
Ras signaling pathway
Rap1 signaling pathway
cGMP-PKG signaling pathway
cAMP signaling pathway
Chemokine signaling pathway
FoxO signaling pathway
Sphingolipid signaling pathway
PI3K-Akt signaling pathway
Vascular smooth muscle contraction
VEGF signaling pathway
Focal adhesion
Gap junction
Signaling pathways regulating pluripotency of stem cells
Natural killer cell mediated cytotoxicity
T cell receptor signaling pathway
B cell receptor signaling pathway
Fc epsilon RI signaling pathway
Fc gamma R-mediated phagocytosis
Long-term potentiation
Neurotrophin signaling pathway
Serotonergic synapse
Long-term depression
Regulation of actin cytoskeleton
Insulin signaling pathway
GnRH signaling pathway
Progesterone-mediated oocyte maturation
Estrogen signaling pathway
Melanogenesis
Prolactin signaling pathway
Thyroid hormone signaling pathway
Oxytocin signaling pathway
Alcoholism
Tuberculosis
Hepatitis C
Hepatitis B
Influenza A
Pathways in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Colorectal cancer
Renal cell carcinoma
Pancreatic cancer
Endometrial cancer
Glioma
Prostate cancer
Melanoma
Bladder cancer
Chronic myeloid leukemia
Acute myeloid leukemia
Non-small cell lung cancer
Central carbon metabolism in cancer
Choline metabolism in cancer
NetPath Pathway IL5 Signaling Pathway
IL2 Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Angiogenesis
B cell activation
EGF receptor signaling pathway
Endothelin signaling pathway
FGF signaling pathway
Inflammation mediated by chemokine and cytokine signaling pathway
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
Integrin signalling pathway
Interleukin signaling pathway
PDGF signaling pathway
T cell activation
VEGF signaling pathway
Ras Pathway
Angiotensin II-stimulated signaling through G proteins and beta-arrestin
CCKR signaling map ST
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
Endothelins
BCR signaling pathway
GMCSF-mediated signaling events
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
CDC42 signaling events
SHP2 signaling
mTOR signaling pathway
IL2-mediated signaling events
IGF1 pathway
Ras signaling in the CD4+ TCR pathway
Ceramide signaling pathway
ErbB1 downstream signaling
ErbB2/ErbB3 signaling events
PDGFR-beta signaling pathway
p38 signaling mediated by MAPKAP kinases
Nongenotropic Androgen signaling
Internalization of ErbB1
CXCR3-mediated signaling events
Signaling events mediated by Stem cell factor receptor (c-Kit)
Signaling events mediated by VEGFR1 and VEGFR2
Class I PI3K signaling events mediated by Akt
Trk receptor signaling mediated by the MAPK pathway
Downstream signaling in na&#xef
Regulation of retinoblastoma protein
Signaling events mediated by focal adhesion kinase
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Insulin Signalling
Reactome Stimuli-sensing channels
GP1b-IX-V activation signalling
CREB phosphorylation through the activation of Ras
CD209 (DC-SIGN) signaling
RAF activation
MAP2K and MAPK activation
Negative feedback regulation of MAPK pathway
Negative regulation of MAPK pathway
WikiPathways Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
TCR Signaling Pathway
Senescence and Autophagy in Cancer
EPO Receptor Signaling
Regulation of Actin Cytoskeleton
IL-2 Signaling Pathway
Insulin Signaling
EGF/EGFR Signaling Pathway
MAPK Cascade
MAPK Signaling Pathway
TGF beta Signaling Pathway
Signaling of Hepatocyte Growth Factor Receptor
Kit receptor signaling pathway
Extracellular vesicle-mediated signaling in recipient cells
IL-3 Signaling Pathway
Cardiac Hypertrophic Response
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
RAF/MAP kinase cascade
Iron uptake and transport
Nanoparticle-mediated activation of receptor signaling
PDGF Pathway
Retinoblastoma (RB) in Cancer
BDNF signaling pathway
Integrated Pancreatic Cancer Pathway
Oncostatin M Signaling Pathway
Corticotropin-releasing hormone
Interleukin-11 Signaling Pathway
AGE/RAGE pathway
TNF alpha Signaling Pathway
B Cell Receptor Signaling Pathway
Prostate Cancer
Signaling Pathways in Glioblastoma
Endothelin Pathways
TWEAK Signaling Pathway
FSH signaling pathway
Leptin signaling pathway
Rap1 signalling
Integrin-mediated Cell Adhesion
GP1b-IX-V activation signalling
MicroRNAs in cardiomyocyte hypertrophy
IL-5 Signaling Pathway
References
Ref 521624ClinicalTrials.gov (NCT00100672) Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer. U.S. National Institutes of Health.
Ref 527280Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 1;10(21):7244-51.
Ref 526998Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53.